Similar Papers

Paper Title
Journal
Date
Author
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Panagiotis A Konstantinopoulos ...
Journal of Clinical Oncology | VOL. 41
Panagiotis A Konstantinopoulos, et. al.Panagiotis A Konstantinopoulos ...
29 Sep 2022
Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Owen A O'Connor ... Bertrand Coiffier
Blood | VOL. 116
Owen A O'Connor, et. al.Owen A O'Connor ... Bertrand Coiffier
19 Nov 2010
Tumor board presentation of a woman with metastatic, hormone receptor‐positive, mismatch repair‐deficient endometrial cancer
Jennifer A Bennett ... Katherine C Kurnit
CA: A Cancer Journal for Clinicians | VOL. 72
Jennifer A Bennett, et. al.Jennifer A Bennett ... Katherine C Kurnit
25 Jan 2022
Abstract OT1-18-05: A multicenter, open-label, phase 2 study of Imprime PGG and pembrolizumab in patients with metastatic breast cancer who have progressed through prior hormonal therapy
Alison Stopeck ... Jose Iglesias
Cancer Research | VOL. 82
Alison Stopeck, et. al.Alison Stopeck ... Jose Iglesias
15 Feb 2022
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements ... Angeles Alvarez Secord
Gynecologic oncology | VOL. 193
Aine Clements, et. al.Aine Clements ... Angeles Alvarez Secord
23 Jan 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
David M O'Malley ... Michele Maio
Gynecologic oncology | VOL. 193
David M O'Malley, et. al.David M O'Malley ... Michele Maio
22 Jan 2025
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Michael D Toboni ... Nathaniel Jones
Gynecologic oncology | VOL. 193
Michael D Toboni, et. al.Michael D Toboni ... Nathaniel Jones
20 Jan 2025
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
M Schaafsma ... N.E Van Trommel
Gynecologic oncology | VOL. 193
M Schaafsma, et. al.M Schaafsma ... N.E Van Trommel
17 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.